3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
92
Genitourinary
10
Thoracic
9
Head & Neck
9
Breast
9
Endocrine
6
Gynecologic
4
Tumor-Agnostic
3
Sarcoma
2
Other solid neoplasm
2
NET
1
Lymphoid
1
Dermatologic
1
Conditions
Pancreatic Neuroendocrine Tumors, WHO Grade I-II
1
Interventions
lutetium Lu 177 dotatate
41
Everolimus
38
Magnetic Resonance Spectroscopy
18
Temozolomide
17
lanreotide
16
gallium Ga 68 dotatate
15
Octreotide
14
pembrolizumab
13
Nivolumab
13
Capecitabine
12
cabozantinib
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
11
surufatinib
9
pasireotide
9
Sunitinib
9
Specimen Handling
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Lutetium-177
8
Carboplatin
8
amino-acid, glucose, and electrolyte solution
6
Ipilimumab
6
Ga(III)-DOTATOC
6
Fluorodeoxyglucose F18
6
Etoposide
6
Cisplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
copper dotatate CU-64
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Radiofrequency Ablation
×
NET
×
Clear all
NCT05243082
2023-03-30
ERFA-PNET
Oslo University Hospital
Phase NA
Recruiting
20 enrolled